

Mark E Layton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3644036/publications.pdf>

Version: 2024-02-01

7
papers

191
citations

1307594

7
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

311
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Advances in the Development of NR2B Subtype-Selective NMDA Receptor Antagonists. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 697-709.	2.1	62
2	3-Aryl-5-phenoxyethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3129-3133.	2.2	41
3	Benzoxazinone aryl sulfonamides as potent, selective Na v 1.7 inhibitors with in vivo efficacy in a preclinical pain model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2683-2688.	2.2	32
4	Discovery of 3-Substituted Aminocyclopentanes as Potent and Orally Bioavailable NR2B Subtype-Selective NMDA Antagonists. <i>ACS Chemical Neuroscience</i> , 2011, 2, 352-362.	3.5	23
5	Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1). <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 859-867.	2.1	17
6	Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 312-317.	2.8	8
7	Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1260-1264.	2.2	8